Changho Han

Dr. Changho Han

Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
Changho HanChangho Han
Changho Han
EKEun Hoo Kim
Eun Hoo Kim
DCDavid A. Colby
David A. Colby

6 March 2013 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Changho HanChangho Han
Changho Han
ASAmy E. Salyer
Amy E. Salyer
EKEun Hoo Kim
Eun Hoo Kim
XJXinyi Jiang
Xinyi Jiang
RJRachel E. Jarrard
Rachel E. Jarrard
DCDavid A. Colby
David A. Colby

28 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SHShihan He
Shihan He
TSTimothy J. Senter
Timothy J. Senter
JPJonathan Pollock
Jonathan Pollock
Changho HanChangho Han
Changho Han
SUSunil Kumar Upadhyay
Sunil Kumar Upadhyay
JGJolanta Grembecka
Jolanta Grembecka
The protein–protein interaction (PPI) between menin and mixed lineage leukemia (MLL) plays a critical role in acute leukemias, and inhibition of this interaction represents a new potential therapeutic strategy for MLL leukemias. We report development of a novel class of small-molecule inhibitors of the menin–MLL interaction, the hydroxy- and aminomethylpiperidine compounds, which originated from HTS of ∼288000 small molecules. We determined menin–inhibitor co-crystal structures and found that these compounds closely mimic all key interactions of MLL with menin. Extensive crystallography studies combined with structure-based design were applied for optimization of these compounds, resulting in MIV-6R, which inhibits the menin–MLL interaction with IC50 = 56 nM. Treatment with MIV-6 demonstrated strong and selective effects in MLL leukemia cells, validating specific mechanism of action. Our studies provide novel and attractive scaffold as a new potential therapeutic approach for MLL leukemias and demonstrate an example of PPI amenable to inhibition by small molecules.

21 March 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
EGEllen J. Gunn
Ellen J. Gunn
JWJohn T. Williams
John T. Williams
DHDaniel T. Huynh
Daniel T. Huynh
MIMichael J. Iannotti
Michael J. Iannotti
Changho HanChangho Han
Changho Han
JKJulia Kirshner
Julia Kirshner
Multiple myeloma (MM) is an incurable plasma cell malignancy where nearly all patients succumb to a relapse. The current preclinical models of MM target the plasma cells, constituting the bulk of the tumor, leaving the cancer stem cells to trigger a relapse. Utilizing a three-dimensional tissue culture system where cells were grown in extracellular matrix designed to reconstruct human bone marrow, we tested the anti-multiple myeloma cancer stem cell (MM-CSC) potential of two natural product inhibitors of nuclear factor κB (NFκB). Here we show that parthenolide and andrographolide are potent anti-MM-CSC agents. Both natural products demonstrated preferential toxicity toward MM-CSCs over non-tumorigenic MM cells. Addition of the bone marrow stromal compartment abrogated andrographolide activity while having no effect on parthenolide cytoxicity. This is the first report of a natural product with anti-CSC activity in myeloma, suggesting that it has the potential to improve the survival of patients with MM by eliminating the relapse-causing MM-CSCs.

20 December 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JTJianhua Tian
Jianhua Tian
KTKevin B. Teuscher
Kevin B. Teuscher
EAErin R. Aho
Erin R. Aho
JAJoseph R. Alvarado
Joseph R. Alvarado
JMJonathan J. Mills
Jonathan J. Mills
SFStephen W. Fesik
Stephen W. Fesik

14 November 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JMJonathan D. Macdonald
Jonathan D. Macdonald
SSSelena Chacón Simon
Selena Chacón Simon
Changho HanChangho Han
Changho Han
FWFeng Wang
Feng Wang
JSJ. Grace Shaw
J. Grace Shaw
SFStephen W. Fesik
Stephen W. Fesik